Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | RPA1 | P27694 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.43 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.43 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13567915 | 0.85 | ANO1 (0.44) | PIK3CATSHRCA2MAPT | |
| SCHEMBL869116 | 0.83 | CA2 (0.65) | PIK3CATSHRCA2RPA1HDAC3 | |
| SCHEMBL21090110 | 0.83 | PIK3CA (0.58) | PIK3CATSHRCNR2CA2RPA1 | |
| SCHEMBL1699590 | 0.82 | MAOA (0.50) | PIK3CAALDH1A1HTT | |
| SCHEMBL1136782 | 0.82 | TSHR (0.53) | PIK3CATSHRCA2KMT2ASMN1; SMN2 | |
| SCHEMBL23869399 | 0.82 | PIK3CA (0.54) | PIK3CATSHRCNR2CA2RPA1 | |
| SCHEMBL10272184 | 0.81 | PIK3CA (0.49) | PIK3CATSHRCNR2CA2RPA1 | |
| SCHEMBL27835202 | 0.81 | PIK3CA (0.56) | PIK3CATSHRCNR2CA2RPA1 | |
| SCHEMBL11520973 | 0.81 | PIK3CA (0.56) | PIK3CATSHRCNR2CA2RPA1 | |
| SCHEMBL3396522 | 0.81 | PIK3CA (0.56) | PIK3CATSHRCA2RPA1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117623893-A | Preparation method of 5-hydroxy-1-indenone | 阜新清稷升科技有限公司 | 2024-03-01 | — | — | CN | claimed |
| CN-117623893-A | Preparation method of 5-hydroxy-1-indenone | 阜新清稷升科技有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117623893-A | Preparation method of 5-hydroxy-1-indenone | 阜新清稷升科技有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-11-09 | — | — | US | disclosed |
| EP-2588450-B1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES INC (US) | 2017-05-24 | — | — | EP | disclosed |
| EP-2588450-B1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES INC (US) | 2017-05-24 | — | — | EP | disclosed |
| CN-103980184-B | Piperidine compounds, medical composition and its use containing this compound | 爱思开生物制药株式会社 | 2016-08-24 | — | — | CN | disclosed |
| US-9102614-B2 | Naphth-2-ylacetic acid derivatives to treat AIDS | GILEAD SCIENCES, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-9102614-B2 | Naphth-2-ylacetic acid derivatives to treat AIDS | GILEAD SCIENCES, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-9102614-B2 | Naphth-2-ylacetic acid derivatives to treat AIDS | GILEAD SCIENCES, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20130203727-A1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203727-A1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203727-A1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2588450-A1 | NAPHT- 2 -YLACETIC ACID DERIVATIVES TO TREAT AIDS | Gilead Sciences, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| CN-101133037-B | Six-membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORP | 2012-05-09 | — | — | CN | disclosed |
| WO-2012003497-A1 | NAPHT- 2 -YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003497-A1 | NAPHT- 2 -YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| CN-102186840-A | Piperidine compounds, pharmaceutical compositions containing the same and uses thereof | SK HOLDINGS CO LTD | 2011-09-14 | — | — | CN | disclosed |
| CN-101133037-A | Six-membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORP (JP) | 2008-02-27 | — | — | CN | disclosed |
| CN-1124960-A | Indole derivatives as 5-HT1A and/or 5-HT2 ligands | BOEHRINGER INGELHEIM ITALIA (IT) | 1996-06-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | ATG7, GOT1, LIPC | PIK3CA 2562/4885TSHR 4173/4885CNR2 3626/4885 |
| US-20130203727-A1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | NFATC1, AADAT, ACAT1 | PIK3CA 2901/4885TSHR 4399/4885CNR2 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.